» Articles » PMID: 20693500

Multiple Anticancer Activities of EF24, a Novel Curcumin Analog, on Human Ovarian Carcinoma Cells

Overview
Journal Reprod Sci
Publisher Springer
Date 2010 Aug 10
PMID 20693500
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Curcumin, a component of turmeric, has been reported to exhibit potential antitumor activities. This study assessed the effects of a novel synthetic curcumin analog, EF24, on proliferation, apoptosis, and vascular endothelial growth factor (VEGF) regulation in platinum-sensitive (IGROV1) and platinum-resistant (SK-OV-3) human ovarian cancer cells. EF24 time- and dose-dependently suppressed the growth of both cell lines and synergized with cisplatin to induce apoptosis. Although treatment with EF24 had no significant effect on VEGF messenger RNA (mRNA) expression,VEGF protein secretion into conditioned media was dose-dependently reduced with EF24 demonstrating ∼8-fold greater potency than curcumin (P < .05). EF24 significantly inhibited hydrogen peroxide (H(2)O(2))-induced VEGF expression, as did the phenolic antioxidant tert-butylhydroquinone (t-BHQ). EF24 upregulated cellular antioxidant responses as observed by the suppression of reactive oxygen species (ROS) generation and activation of antioxidant response element (ARE)-dependent gene transcription. Given its high potency, EF24 is an excellent lead candidate for further development as an adjuvant therapeutic agent in preclinical models of ovarian cancer.

Citing Articles

Anticarcinogenic Potency of EF24: An Overview of Its Pharmacokinetics, Efficacy, Mechanism of Action, and Nanoformulation for Drug Delivery.

Sazdova I, Keremidarska-Markova M, Dimitrova D, Mitrokhin V, Kamkin A, Hadzi-Petrushev N Cancers (Basel). 2023; 15(22).

PMID: 38001739 PMC: 10670065. DOI: 10.3390/cancers15225478.


Curcumin and Its Derivatives as Potential Antimalarial and Anti-Inflammatory Agents: A Review on Structure-Activity Relationship and Mechanism of Action.

Jamil S, Hamizah Ali A, Feroz S, Lam S, Kartini Agustar H, Abd Razak M Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111366 PMC: 10146798. DOI: 10.3390/ph16040609.


The Apoptotic Activity of Curcumin Against Oral Cancer Cells Without Affecting Normal Cells in Comparison to Paclitaxel Activity.

Hussein H, Khaphi F Appl Biochem Biotechnol. 2023; 195(8):5019-5033.

PMID: 37032374 DOI: 10.1007/s12010-023-04454-5.


Targeting the Cancer Stem Cells in Endocrine Cancers with Phytochemicals.

Gor R, Ramachandran I, Ramalingam S Curr Top Med Chem. 2022; 22(31):2589-2597.

PMID: 36380414 DOI: 10.2174/1567205020666221114112814.


Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability.

Nocito M, De Luca A, Prestia F, Avena P, Padula D, Zavaglia L Biomedicines. 2021; 9(10).

PMID: 34680593 PMC: 8533288. DOI: 10.3390/biomedicines9101476.